Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4615 Dosimetry, efficacy and safety of radiolabelled somatostatin receptor antagonist in patients with metastatic pheochromocytoma or paraganglioma

Introduction: Metastatic pheochromocytomas and paragangliomas (mPPGLs) are rare neuroendocrine tumours with a heterogenous phenotype and a variable treatment response. The SSTR antagonist [177Lu]Lu177Lu-DOTA-JR11 (177Lu-JR11) offers potentially increased tumour doses than standard radioligand therapy (RLT) with [177Lu]Lu-DOTA-TOC (177Lu-TOC).

Conference:

Presenting Author: Lider S

Authors: Lider Burciulescu S, Schmidt F, McDougall L, Bernhardt P, Mushaweh A,

Keywords: Metastatic PPGL, radioligand therapy, somatostatin receptor antagonist, dosimetry,

#3692 Improvement of lung NET management through standardized care – A Swiss nationwide observational study

Introduction: Typical (TC) and atypical carcinoids (AC) are the most common neuroendocrine tumors (NETs) of the lung. Being a rare disease, the management of these tumors varies widely among Swiss centers. The impact of guidelines introduced in 2015 is unknown.

Conference:

Presenting Author: Schmidlin M

Authors: Schmidlin M, Sadowski S, Siebenhüner A, Wild D, Christ E,

Keywords: pulmonary carcinoid, survival analysis, registry,

#3553 Gamma-glutamyltransferase as an indicator of hepatic tumor burden in neuroendocrine tumors

Introduction: In patients with neuroendocrine tumors (NETs) and liver metastasis, elevation of gamma-glutamyltransferase (GGT) is considered to be a sign of hepatic progression. However, there are no data supporting this assumption.

Conference:

Presenting Author: Schmidt B

Authors: Schmidt B, Leiderer M, Amin T, Viol F, Adam G,

Keywords: gamma glutamyltransferase, hepatic tumor burden, neuroendocrine tumor, liver metastasis, biomarker,

#2884 An Infectious Diseases Specialist NET Patient Looks at Management of NETs

Introduction: Medical specialties may develop practices minimally influenced by other specialties.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Schmid G,

Keywords: neuroendocrine, everolimus, somatostatin analogue, drug levels,

#1596 Triple Tracer Imaging Approach for the Non-Invasive Assessment of Chemokine Receptor 4 Expression in Gastroenteropancreatic Neuroendocrine Tumors

Introduction: The theranostic twins [68Ga]Pentixafor and [177Lu]Pentixather for chemokine-directed endoradiotherapy (ERT) were recently developed.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Werner R

Authors: Werner R, Weich A, Higuchi T, Schmid J, Schirbel A,

Keywords: Neuroendocrine tumor, [68Ga]Pentixafor, CXCR4, PRRT, PET/CT,